Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis
Primary Purpose
Osteoarthritis
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Meloxicam
NSAID
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis
Eligibility Criteria
Inclusion Criteria:
- Males and females over the age of 18
- The patient, if female and of reproductive potential (i.e. neither surgically sterilized nor post-menopausal), must be practicing adequate contraception (e.g. intrauterine device, contraceptive pills, Depo-Provera, or implant or double barrier device) for at least three months prior to and for the duration of their trial participation and must have a negative pregnancy test at screening. Abstinence is not considered to be an acceptable method of contraception. (It should be noted that NSAIDs might interfere with the effectiveness of intrauterine devices)
The patient must have a documented diagnosis of at least one of the following:
- Osteoarthritis of the hip
- Osteoarthritis of the knee
- Osteoarthritis of the hand or
- Osteoarthritis of the spine - Patients must have radiographic confirmation of the diagnosis
- The patient is willing to change or requires a change in current prescription NSAID therapy or requires initiation of prescription NSAID therapy for treatment of OA of the hip, knee, hand or spine
- The patient intends to remain a member of their present Managed Care Organization (MCO) for the duration of the trial
- The patient is willing to comply with instructions and to provide written informed consent
Exclusion Criteria:
- The patient has a known or suspected hypersensitivity to the trial drugs or their excipients, analgesics, antipyretics or NSAIDS (prescription or over-the-counter)
- The patient has received an investigational drug or used an investigational device within 30 days prior to entering the trial
- In the opinion of the investigator the patient has any disease or condition that may result in altered absorption, excess accumulation or impaired metabolism or excretion of the trial medication
- The patient has a history of recurrent peptic ulcer or history (within the past 6 months) of gastrointestinal perforation, peptic ulceration documented by endoscopy or radiography, symptomatic hiatal hernia requiring daily treatment or any history of a gastrointestinal tract hemorrhage, except simple hemorrhoidal bleeding
- The patient is currently on coumadin or might be placed on coumadin during the course of the clinical trial
- Patients with dementia, i.e. incapable of following directions or complying with the study protocol
- Patients with co-existing rheumatological disorders including rheumatoid arthritis
- The patient has previously participated in this trial
- Patients with coexisting fibromyalgia or ankylosing spondylitis
- Patient is pregnant or lactating
- Patient has severe hepatic failure
- Patient has non-dialysed renal failure
- Patient has history of GI bleed within the past 6 months
- Patient has history of cerebrovascular bleeding or other bleeding disorders
- Patient is receiving concomitant lithium, heparin or ticlopidine therapy
- Patient has a history of leukopenia (White Blood Cell count < 3500/mm³)
- The patient has a history of platelet count below the lower limit of normal or has a documented abnormal prothrombin time (PT) or partial thromboplastin time (PTT)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Meloxicam
Usual care prescription NSAID
Arm Description
Outcomes
Primary Outcome Measures
Percentage of treatment successes and failures in patients randomized to meloxicam 7.5 mg vs.usual care prescription NSAIDs
Secondary Outcome Measures
Investigator's Global Assessment of Disease Activity (Likert)
Patient's overall Assessment of pain over the past week on a visual analogue scale (VAS)
Patient's Assessment of Health Status (VAS)
Patient's Assessment of Satisfaction of Health
Utility Index (VAS)
Western Ontario and Mc Master University Osteoarthritis Index (WOMAC)
Medication Compliance
Disability Index
Permanent Discontinuation of Study Medication related to lack of efficacy
Incidence and intensity of adverse events
Permanent Discontinuation of Study Medication related to adverse event
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02183064
Brief Title
Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis
Official Title
A Multi-Center, Randomized, Parallel-Group, Open-Label Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis of the Hip, Knee, Hand or Spine
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
October 1998 (undefined)
Primary Completion Date
November 2000 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
Study to compare the percentage of treatment successes or failures in patients randomized to meloxicam 7.5 mg vs. usual care prescription NSAIDs. Additionally, health care utilization, efficacy and safety of patients in a managed healthcare setting with osteoarthritis (OA) of the hip, knee, hand or spine will be assessed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1309 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Meloxicam
Arm Type
Experimental
Arm Title
Usual care prescription NSAID
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Meloxicam
Intervention Type
Drug
Intervention Name(s)
NSAID
Primary Outcome Measure Information:
Title
Percentage of treatment successes and failures in patients randomized to meloxicam 7.5 mg vs.usual care prescription NSAIDs
Time Frame
up to 6 month
Secondary Outcome Measure Information:
Title
Investigator's Global Assessment of Disease Activity (Likert)
Time Frame
Screening (Day 0), after six month (Day 180)
Title
Patient's overall Assessment of pain over the past week on a visual analogue scale (VAS)
Time Frame
Day 0, 30, 60, 90, 120, 150, 180
Title
Patient's Assessment of Health Status (VAS)
Time Frame
Day 0, 30, 60, 90, 120, 150, 180
Title
Patient's Assessment of Satisfaction of Health
Time Frame
Day 0, 30, 60, 90, 120, 150, 180
Title
Utility Index (VAS)
Time Frame
Day 0, 30, 60, 90, 120, 150, 180
Title
Western Ontario and Mc Master University Osteoarthritis Index (WOMAC)
Time Frame
Day 0, 30, 60, 90, 120, 150, 180
Title
Medication Compliance
Time Frame
Day 30, day 180
Title
Disability Index
Time Frame
Screening (Day 0), after six month (Day 180)
Title
Permanent Discontinuation of Study Medication related to lack of efficacy
Time Frame
up to day 180
Title
Incidence and intensity of adverse events
Time Frame
from day 30 until day 180
Title
Permanent Discontinuation of Study Medication related to adverse event
Time Frame
from day 30 until day 180
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males and females over the age of 18
The patient, if female and of reproductive potential (i.e. neither surgically sterilized nor post-menopausal), must be practicing adequate contraception (e.g. intrauterine device, contraceptive pills, Depo-Provera, or implant or double barrier device) for at least three months prior to and for the duration of their trial participation and must have a negative pregnancy test at screening. Abstinence is not considered to be an acceptable method of contraception. (It should be noted that NSAIDs might interfere with the effectiveness of intrauterine devices)
The patient must have a documented diagnosis of at least one of the following:
Osteoarthritis of the hip
Osteoarthritis of the knee
Osteoarthritis of the hand or
Osteoarthritis of the spine - Patients must have radiographic confirmation of the diagnosis
The patient is willing to change or requires a change in current prescription NSAID therapy or requires initiation of prescription NSAID therapy for treatment of OA of the hip, knee, hand or spine
The patient intends to remain a member of their present Managed Care Organization (MCO) for the duration of the trial
The patient is willing to comply with instructions and to provide written informed consent
Exclusion Criteria:
The patient has a known or suspected hypersensitivity to the trial drugs or their excipients, analgesics, antipyretics or NSAIDS (prescription or over-the-counter)
The patient has received an investigational drug or used an investigational device within 30 days prior to entering the trial
In the opinion of the investigator the patient has any disease or condition that may result in altered absorption, excess accumulation or impaired metabolism or excretion of the trial medication
The patient has a history of recurrent peptic ulcer or history (within the past 6 months) of gastrointestinal perforation, peptic ulceration documented by endoscopy or radiography, symptomatic hiatal hernia requiring daily treatment or any history of a gastrointestinal tract hemorrhage, except simple hemorrhoidal bleeding
The patient is currently on coumadin or might be placed on coumadin during the course of the clinical trial
Patients with dementia, i.e. incapable of following directions or complying with the study protocol
Patients with co-existing rheumatological disorders including rheumatoid arthritis
The patient has previously participated in this trial
Patients with coexisting fibromyalgia or ankylosing spondylitis
Patient is pregnant or lactating
Patient has severe hepatic failure
Patient has non-dialysed renal failure
Patient has history of GI bleed within the past 6 months
Patient has history of cerebrovascular bleeding or other bleeding disorders
Patient is receiving concomitant lithium, heparin or ticlopidine therapy
Patient has a history of leukopenia (White Blood Cell count < 3500/mm³)
The patient has a history of platelet count below the lower limit of normal or has a documented abnormal prothrombin time (PT) or partial thromboplastin time (PTT)
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/107/107.210_U01-3301.pdf
Description
Related Info
Learn more about this trial
Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis
We'll reach out to this number within 24 hrs